Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)
Phase 3
Completed
- Conditions
- Dry Eye Syndromes
- Registration Number
- NCT00549289
- Lead Sponsor
- Sirion Therapeutics, Inc.
- Brief Summary
The purpose of this phase III, open-label study is to determine the safety and tolerability of cyclosporine in the treatment of dry eye syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Diagnosis of dry eye syndrome
Exclusion Criteria
- Intraocular or refractive surgery in the study eye within 3 months prior to study start
- Unwilling to discontinue use of contact lenses during the study
- Pregnancy or lactation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which cyclosporine modulates T-cell activity in dry eye syndrome?
How does cyclosporine compare to other immunosuppressants like lifitegrast in treating dry eye symptoms?
Which ocular surface biomarkers correlate with cyclosporine response in phase III trials for dry eye syndrome?
What are the long-term safety profiles of cyclosporine eye drops in chronic dry eye patients?
Are there combination therapies involving cyclosporine and anti-inflammatory agents for dry eye syndrome?
Trial Locations
- Locations (1)
Clayton Eye Center
🇺🇸Morrow, Georgia, United States
Clayton Eye Center🇺🇸Morrow, Georgia, United States